A LITERATURE REVIEW OF HEALTH ECONOMIC ASSESSMENTS, HEALTH CARE RESOURCE UTILIZATION (HCRU), AND HEALTH RELATED QUALITY-OF-LIFE (HRQOL) IN PATIENTS WITH GASTRIC CANCER (GC)
Author(s)
van Dalfsen N1, Contente M2, Gudala K3, Lee D1, Maglinte G4, Calvo E5
1BresMed Health Solutions Ltd., Sheffield, UK, 2Bristol-Myers Squibb, Uxbridge, Middlesex, UK, 3BresMed Health Solutions Ltd., Gurugram, India, 4Bristol-Myers Squibb, Princeton, NJ, USA, 5START Madrid, Centro Integral Oncologico Clara Campal, Madrid, Spain
OBJECTIVES: To review the published evidence on health economic assessments/modelling, cost of illness/HCRU, and HRQOL/utility studies of pharmacological treatments in unresectable, advanced or recurrent GC. METHODS: Three targeted literature reviews (TLRs) were completed with searches performed in PubMed and Embase (restricted to the last 10 years), key international health technology assessment websites and databases, and recent relevant conference websites. Searches were not restricted by treatment line RESULTS: In total, 65 studies were found (economic modelling [21], HCRU and costs [25] and HRQOL [19, of which 8 reported utility data]). Twenty economic modelling studies were evaluations of first-line (1L) or second-line (2L) treatments. Where third-line (3L) modelling was performed, data was mostly taken from earlier lines. Thirteen studies were cost-effectiveness studies, mostly reporting three-state Markov models; 8 were cost-minimisation studies. HCRU and costs were mostly reported for 1L/2L settings and were not uniform across regions. Where information was reported, increase in treatment line appeared to increase length of inpatient stays and to reduce treatment duration. Utility studies reported mainly baseline utilities (0.70 - 0.75). Few studies reported post-progression utilities (0.60-0.69). One study at 2L reported utility decrements for disease progression (0.07), hospitalisation (0.08) and time-to-death (0.37, ≤3 months to death; 0.23, 3 to ≤9 months to death). Literature indicates HRQOL to be mainly driven by emotional functioning (EF), along with global quality of life (during or after treatment). EF appears to improve with treatment indicating that EF can be considered important in patients with GC. CONCLUSIONS: TLRs show that some literature exists on cost-effectiveness, HCRU, and HRQOL for advanced GC in 1L and 2L. However, further evidence generation is still warranted, mainly in the 3L setting.
Conference/Value in Health Info
2017-11, ISPOR Europe 2017, Glasgow, Scotland
Value in Health, Vol. 20, No. 9 (October 2017)
Code
PCN143
Topic
Economic Evaluation
Topic Subcategory
Cost-comparison, Effectiveness, Utility, Benefit Analysis
Disease
Oncology